Cargando…
A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
INTRODUCTION: HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of H...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178998/ https://www.ncbi.nlm.nih.gov/pubmed/28005906 http://dx.doi.org/10.1371/journal.pone.0167397 |
_version_ | 1782485292986400768 |
---|---|
author | Hamy, Anne-Sophie Bonsang-Kitzis, Hélène Lae, Marick Moarii, Matahi Sadacca, Benjamin Pinheiro, Alice Galliot, Marion Abecassis, Judith Laurent, Cecile Reyal, Fabien |
author_facet | Hamy, Anne-Sophie Bonsang-Kitzis, Hélène Lae, Marick Moarii, Matahi Sadacca, Benjamin Pinheiro, Alice Galliot, Marion Abecassis, Judith Laurent, Cecile Reyal, Fabien |
author_sort | Hamy, Anne-Sophie |
collection | PubMed |
description | INTRODUCTION: HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. METHODS: We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). RESULTS: We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the “Immunity” metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28–11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36–0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). CONCLUSION: The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation. |
format | Online Article Text |
id | pubmed-5178998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-51789982017-01-04 A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways Hamy, Anne-Sophie Bonsang-Kitzis, Hélène Lae, Marick Moarii, Matahi Sadacca, Benjamin Pinheiro, Alice Galliot, Marion Abecassis, Judith Laurent, Cecile Reyal, Fabien PLoS One Research Article INTRODUCTION: HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. METHODS: We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). RESULTS: We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the “Immunity” metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28–11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36–0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). CONCLUSION: The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation. Public Library of Science 2016-12-22 /pmc/articles/PMC5178998/ /pubmed/28005906 http://dx.doi.org/10.1371/journal.pone.0167397 Text en © 2016 Hamy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hamy, Anne-Sophie Bonsang-Kitzis, Hélène Lae, Marick Moarii, Matahi Sadacca, Benjamin Pinheiro, Alice Galliot, Marion Abecassis, Judith Laurent, Cecile Reyal, Fabien A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways |
title | A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways |
title_full | A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways |
title_fullStr | A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways |
title_full_unstemmed | A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways |
title_short | A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways |
title_sort | stromal immune module correlated with the response to neoadjuvant chemotherapy, prognosis and lymphocyte infiltration in her2-positive breast carcinoma is inversely correlated with hormonal pathways |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178998/ https://www.ncbi.nlm.nih.gov/pubmed/28005906 http://dx.doi.org/10.1371/journal.pone.0167397 |
work_keys_str_mv | AT hamyannesophie astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT bonsangkitzishelene astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT laemarick astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT moariimatahi astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT sadaccabenjamin astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT pinheiroalice astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT galliotmarion astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT abecassisjudith astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT laurentcecile astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT reyalfabien astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT hamyannesophie stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT bonsangkitzishelene stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT laemarick stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT moariimatahi stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT sadaccabenjamin stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT pinheiroalice stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT galliotmarion stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT abecassisjudith stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT laurentcecile stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways AT reyalfabien stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways |